利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

56 条记录 (耗时 0.031 秒)

    Bispecific and oligospecific mono-and oligovalent receptors, the preparation and use thereof
    22.
    发明授权
    Bispecific and oligospecific mono-and oligovalent receptors, the preparation and use thereof 失效
    双特异性和寡特异性单和低价受体，其制备和应用

    公开(公告)号：US5591828A

    公开(公告)日：1997-01-07

    申请号：US317612

    申请日：1994-09-29

    申请人： Klaus Bosslet ,  Peter Hermentin ,  Gerhard Seemann ,  Ludwig Kuhlmann ,  Axel Steinstr asser

    发明人： Klaus Bosslet ,  Peter Hermentin ,  Gerhard Seemann ,  Ludwig Kuhlmann ,  Axel Steinstr asser

    IPC分类号： A61K31/00 ,  A61K38/00 ,  A61K39/395 ,  A61P35/00 ,  C07K1/22 ,  C07K14/00 ,  C07K14/705 ,  C07K16/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/46 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/00 ,  C12P21/08 ,  C12R1/91 ,  C07K16/28

    CPC分类号： C07K16/468 ,  C07K16/3007 ,  A61K38/00

    摘要： The invention relates to bispecific and oligospecific, mono- and oligovalent receptors which are prepared by gene manipulation by fusion of DNA coding for F(ab) fragments of antibodies of two or more different specificities by means of suitable linkers. In this connection, one specificity is preferably directed either against an epitope, which is located on the cell membrane or in the interstitium, of a tumor-associated antigen (TAA) or against an epitope in the tumor endothelium (TE), while the other specificities relate to high-molecular or low-molecular weight ligands and react, for example, with the Komplexons ethylenediaminetetraacetate and diethylenetriaminepentaacetate in Y90 complexed form (EDTA-Y90 and DTPA-Y90 respectively). In a particularly preferred embodiment, the binding with the Komplexons takes place on the Komplexon receptor arm via fos-jun interaction (or else avidin-biotin interaction). Other preferred specificities have catalytic properties.

    摘要翻译： 本发明涉及双特异性和寡特异性，单低分子和低聚受体，其通过用适当的接头对通过融合编码两种或多种不同特异性的抗体的F（ab）片段的DNA进行融合来制备。 在这方面，一个特异性优选地针对肿瘤相关抗原（TAA）或肿瘤内皮（TE）中的表位位于细胞膜或间质的表位，而另一个 特异性涉及高分子量或低分子量配体，例如与Y90络合形式的乙二胺四乙酸钴和二亚乙基三胺五乙酸酯反应（分别为EDTA-Y90和DTPA-Y90）。 在特别优选的实施方案中，与Komplexons的结合通过fos-jun相互作用（或者亲和素 - 生物素相互作用）发生在Komplexon受体臂上。 其它优选的特性具有催化性质。

    Bifunctional glycoproteins having a modified carbohydrate complement and their use in tumor-selective therapy
    23.
    发明授权
    Bifunctional glycoproteins having a modified carbohydrate complement and their use in tumor-selective therapy 失效
    具有修饰的碳水化合物补体的双功能糖蛋白及其在肿瘤选择性治疗中的用途

    公开(公告)号：US08552159B2

    公开(公告)日：2013-10-08

    申请号：US10815925

    申请日：2004-04-02

    申请人： Klaus Bosslet ,  Joerg Czech ,  Dieter Hoffmann

    发明人： Klaus Bosslet ,  Joerg Czech ,  Dieter Hoffmann

    IPC分类号： C07K1/00

    CPC分类号： C12N9/0002 ,  A61K38/00 ,  A61K47/62 ,  A61K47/6851 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3046 ,  C07K19/00 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/61

    摘要： Provided herein are carbohydrate complement-modified bifunctional glycoproteins, and their use in tumor-selective therapy. The bifunctional glycoproteins comprise a first component that specifically binds to a tumor-specific antigen and a second component having enzymatic activity by means of which a non-toxic prodrug is cleaved into a cytotoxic drug. The carbohydrate complement comprises at least one exposed carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, N-acetyllactose, glucose and fucose. The modified carbohydrate complement contributes to increased relative concentration of the glycoproteins at the site of the tumor, and enhanced clearance from the general circulation and non-tumor sites.

    摘要翻译： 本文提供了碳水化合物补体修饰的双功能糖蛋白，以及它们在肿瘤选择性治疗中的用途。 双功能糖蛋白包含特异性结合肿瘤特异性抗原的第一组分和具有酶活性的第二组分，通过其将非毒性前体药物切割成细胞毒性药物。 碳水化合物补体包含至少一种选自甘露糖，半乳糖，N-乙酰葡糖胺，N-乙酰乳糖，葡萄糖和岩藻糖的暴露的碳水化合物残基。 修饰的碳水化合物补体有助于增加肿瘤位置处的糖蛋白的相对浓度，并且增强了与一般循环和非肿瘤部位的清除率。

    Antigenic constructs of major histocompatibility complex class I antigens with specific carrier molecules, the preparation and use thereof
    27.
    发明授权
    Antigenic constructs of major histocompatibility complex class I antigens with specific carrier molecules, the preparation and use thereof 失效
    具有特异性载体分子的主要组织相容性复合物I类抗原的抗原构建体，其制备和应用

    公开(公告)号：US06548067B1

    公开(公告)日：2003-04-15

    申请号：US08460569

    申请日：1995-06-02

    申请人： Gerhard Seeman ,  Klaus Bosslet ,  Hans Harald Sedlacek

    发明人： Gerhard Seeman ,  Klaus Bosslet ,  Hans Harald Sedlacek

    IPC分类号： A61K3900

    CPC分类号： B82Y5/00 ,  A61K38/00 ,  A61K47/6898 ,  C07K14/70539 ,  C07K16/00 ,  C07K17/02 ,  C07K2319/00 ,  C07K2319/02

    摘要： Antigenic constructs which result from linkage of major histocompatibility complex (MHC) class I antigens with specific carrier molecules are described. The linkage is effected N- or C-terminally by covalent bonding or, for example, in the case of non-covalent bonding by an avidin/biotin bridge. The specific carrier molecules bind selectively to target cells and are preferably monoclonal antibodies. Processes of genetic manipulation for the preparation of such constructs are indicated. Antigenic constructs according to the invention are used to damage or eliminate target cells.

    摘要翻译： 描述了由主要组织相容性复合体（MHC）I类抗原与特异性载体分子的连接产生的抗原构建体。 通过共价键进行N-或C-末端的连接，或者例如在通过抗生物素蛋白/生物素桥的非共价结合的情况下。 特异性载体分子选择性地结合靶细胞，优选单克隆抗体。 指出用于制备这种构建体的遗传操作过程。 根据本发明的抗原构建体用于损伤或消除靶细胞。